These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 21784708)

  • 1. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis.
    Tasina E; Haidich AB; Kokkali S; Arvanitidou M
    Lancet Infect Dis; 2011 Nov; 11(11):834-44. PubMed ID: 21784708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tigecycline for the treatment of severe infectious diseases: an updated meta-analysis of RCTs.
    Shen F; Han Q; Xie D; Fang M; Zeng H; Deng Y
    Int J Infect Dis; 2015 Oct; 39():25-33. PubMed ID: 26283551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review and Meta-Analysis.
    Ni W; Han Y; Liu J; Wei C; Zhao J; Cui J; Wang R; Liu Y
    Medicine (Baltimore); 2016 Mar; 95(11):e3126. PubMed ID: 26986165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
    Sacchidanand S; Penn RL; Embil JM; Campos ME; Curcio D; Ellis-Grosse E; Loh E; Rose G
    Int J Infect Dis; 2005 Sep; 9(5):251-61. PubMed ID: 16099700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis.
    Wang J; Pan Y; Shen J; Xu Y
    Ann Clin Microbiol Antimicrob; 2017 Apr; 16(1):24. PubMed ID: 28381268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.
    Babinchak T; Ellis-Grosse E; Dartois N; Rose GM; Loh E; ;
    Clin Infect Dis; 2005 Sep; 41 Suppl 5():S354-67. PubMed ID: 16080073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections.
    Falagas ME; Vardakas KZ; Tsiveriotis KP; Triarides NA; Tansarli GS
    Int J Antimicrob Agents; 2014 Jul; 44(1):1-7. PubMed ID: 24602499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
    Garrison MW; Neumiller JJ; Setter SM
    Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of tigecycline: a systematic review and meta-analysis.
    Yahav D; Lador A; Paul M; Leibovici L
    J Antimicrob Chemother; 2011 Sep; 66(9):1963-71. PubMed ID: 21685488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy of 1,025 severely ill patients with complicated infections in a German multicenter study: safety profile and efficacy of tigecycline in different treatment modalities.
    Bodmann KF; Heizmann WR; von Eiff C; Petrik C; Löschmann PA; Eckmann C
    Chemotherapy; 2012; 58(4):282-94. PubMed ID: 23052187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short- versus long-course antibiotic therapy for acute pyelonephritis in adolescents and adults: a meta-analysis of randomized controlled trials.
    Kyriakidou KG; Rafailidis P; Matthaiou DK; Athanasiou S; Falagas ME
    Clin Ther; 2008 Oct; 30(10):1859-68. PubMed ID: 19014841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of tigecycline for the treatment of complicated skin and soft-tissue and intra-abdominal infections: an analysis based on five European observational studies.
    Guirao X; Sánchez García M; Bassetti M; Bodmann KF; Dupont H; Montravers P; Heizmann WR; Capparella MR; Simoneau D; Eckmann C
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii37-44. PubMed ID: 23772045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of tigecycline efficacy and safety in the treatment of complicated skin and skin structure infections - a European perspective.
    Teras J; Gardovskis J; Vaasna T; Kupcs U; Pupelis G; Dukart G; Dartois N; Jouve S; Cooper A;
    J Chemother; 2008 Oct; 20 Suppl 1():20-7. PubMed ID: 19036671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.
    Ellis-Grosse EJ; Babinchak T; Dartois N; Rose G; Loh E; ;
    Clin Infect Dis; 2005 Sep; 41 Suppl 5():S341-53. PubMed ID: 16080072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials.
    McGovern PC; Wible M; El-Tahtawy A; Biswas P; Meyer RD
    Int J Antimicrob Agents; 2013 May; 41(5):463-7. PubMed ID: 23537581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of tigecycline in the treatment of infections in light of the new black box warning.
    Dixit D; Madduri RP; Sharma R
    Expert Rev Anti Infect Ther; 2014 Apr; 12(4):397-400. PubMed ID: 24597542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies.
    Bassetti M; Eckmann C; Bodmann KF; Dupont H; Heizmann WR; Montravers P; Guirao X; Capparella MR; Simoneau D; Sánchez García M
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii5-14. PubMed ID: 23772047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical response and mortality in tigecycline complicated intra-abdominal infection and complicated skin and soft-tissue infection trials.
    Bassetti M; McGovern PC; Wenisch C; Meyer RD; Yan JL; Wible M; Rottinghaus ST; Quintana A
    Int J Antimicrob Agents; 2015 Sep; 46(3):346-50. PubMed ID: 26155003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study.
    Purdy J; Jouve S; Yan JL; Balter I; Dartois N; Cooper CA; Korth-Bradley J
    Clin Ther; 2012 Feb; 34(2):496-507.e1. PubMed ID: 22249106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.